Boston Scientific(US:BSX) Globenewswire·2026-03-31 19:08Core Viewpoint - A class action has been filed against Boston Scientific Corporation for allegedly misleading investors about its projected revenue and growth potential during the class period from July 23, 2025, to February 3, 2026 [1][2]. Group 1: Allegations and Market Impact - The complaint alleges that Boston Scientific misrepresented its revenue outlook and growth potential, downplaying risks from seasonality and macroeconomic factors [2]. - The company aimed to grow its share in the electrophysiology (EP) market at twice the market rate but faced new competition that negatively impacted its U.S. market share and growth potential [2]. - Following the announcement of disappointing fourth quarter and full year 2025 results, including poor U.S. EP sales and guidance for fiscal 2026 that was below expectations, Boston Scientific's stock price dropped over 17%, from $91.62 on February 3, 2026, to $75.50 on February 4, 2026 [3]. Group 2: Shareholder Actions - Shareholders may participate in the class action against Boston Scientific and those wishing to serve as lead plaintiff must submit their papers by May 4, 2026 [4]. - Shareholders are not required to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5]. - The firm has a history of advocating for shareholder rights and aims to help recover losses and improve corporate governance [5].